Cryptococcal meningitis is the second top killer of people living with HIV in South Africa. In the second of a two-part series on access to treatment for the condition, Catherine Tomlinson puts the Spotlight on the drug liposomal amphotericin B (part one looked at flucytosine).
After seemingly endless delays, a critically important drug for the treatment of cryptococcal meningitis was recently approved in South Africa. Yet, while the approval of flucytosine was a major step forward, much more still needs to be done to ensure wide availability of this life-saving medicine for the second leading killer of people living with HIV. Catherine Tomlinson unpacks the details.
Cryptococcal meningitis is the second biggest killer of people living with HIV after tuberculosis (TB). Now, a global initiative, the Ending Cryptococcal Meningitis Deaths by 2030 Strategic Framework aims to get the gold standard drug to treat cryptococcal meningitis – flucytosine – registered in countries that need it. Amy Green reports.